Cyberonics’ Sharpened Focus Buoys Stock 13% In May; OTC Index Off 2.6%
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics' revised NCP vagus nerve stimulation development plan for depression, combined with a sharper focus on epilepsy and fiscal fourth-quarter performance ahead of Wall Street expectations, led to a 12.5% stock gain in May
You may also be interested in...
Cyberonics Cuts Investment In VNS Depression Indication; Q4 Sales Up 64%
Cyberonics expects to scale-back its investment in developing a depression indication for its NeuroCybernetic Prosthesis vagus nerve stimulation system by 25% in fiscal 2003
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.